Vandetanib 300mg (Vandetanib)

Description  of  Caprelsa 300mg (Vandetanib 300mg)

Vandetanib is a generic form of brand name Caprelsa 300mg (Vandetanib 300mg) and is a prescription drug which is used under the guidance of medical practioners.
Caprelsa 300mg (Vandetanib 300mg) belongs to oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell multiplication with the possible for use in a broad range of tumour types.
Caprelsa 300mg (Vandetanib 300mg) was authorized by the FDA for the treatment nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.

INDICATIONS of  Caprelsa 300mg (Vandetanib 300mg)

Caprelsa 300mg (Vandetanib 300mg) is used for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.

MECHANISM OF ACTION  of  Caprelsa 300mg (Vandetanib 300mg)

Vandetanib belongs to targeted therapy which aims and join to the tyrosine kinase receptors and prohibits epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), readjust during transfection (RET), protein tyrosine kinase 6 (BRK), TIE2, EPH kinase receptors and SRC kinase receptors on the surface of the cell. By binding to these receptors Vandetanib Stops an important pathway which advance cell division.

Absorption of  Caprelsa 300mg (Vandetanib 300mg)

Peak plasma concentration is 6 hr (range 4-10 hr) and steady state is 3 months.

Distribution of  Caprelsa 300mg (Vandetanib 300mg)

Bounding of plasma protein is 90% and volume of distribution is 7450L.

Metabolism of  Caprelsa 300mg (Vandetanib 300mg)

Caprelsa 300mg (Vandetanib 300mg) is metabolized by CYP3A4.

Excretion of  Caprelsa 300mg (Vandetanib 300mg)

The drug elimination through feces 44% and via urine collection period of 21 day after single dose.

 SIDE EFFECTS  of  Caprelsa 300mg (Vandetanib 300mg)

Headache, Fatigue, Low blood sugar, Abdominal pain, Poor appetite, Low white blood cell count, Kidney problems, Dry skin, Vomiting, Weakness, Irregular heart beat, Difficulty sleeping, Sensitivity to sunlight, Bleeding, Anemia, Bilirubin, Itching, Heartburn, Cough, Upper respiratory infection, Depression, Weight loss, Diarrhea, Rash, Elevated Liver Enzymes (ALT), Low calcium levels, Acne, High blood pressure, Nausea.

PRECAUTIONS  of  Caprelsa 300mg (Vandetanib 300mg)

Effective CYP3A4 inducers reduced exposure to Caprelsa 300mg (Vandetanib 300mg) by up to 40%; however, no clinically significant effect on exposure to Caprelsa 300mg (Vandetanib 300mg) was observed in the presence of the potent CYP3A4 inhibitors.
Fatal skin reactions, containing Stevens-Johnson syndrome and severe toxic epidermal necrolysis reported; systemic treatment such as corticosteroids may be needed; permanently stop therapy for severe skin reactions.
Interstitial lung disease (ILD), causes in death has been resulted; inhibit Caprelsa 300mg (Vandetanib 300mg) and examine unexplained Dyspnea, cough, and fever; applicable measures should be taken for ILD.
Ischemic cerebrovascular events, haemorrhage, heart failure, diarrhea, hypothyroidism, hypertension, and reversible posterior leukoencephalopathy syndrome, have been observed.
Can cause fetal harm when administered to pregnant women; Do not get pregnancy while getting Caprelsa 300mg (Vandetanib 300mg) and for 4 months following treatment.

DRUG INTERACTION of  Caprelsa 300mg (Vandetanib 300mg)

While interaction with a strong CYP3A4 inducer will decreased Vandetanib plasma concentration. Hence avoid concomitant use of known strong CYP3A4 inducers during Caprelsa 300mg (Vandetanib 300mg) treatment.
When administrating Caprelsa 300mg (Vandetanib 300mg) with drugs that are transported by OCT2 will increased plasma concentration of metformin.
When administering Caprelsa 300mg (Vandetanib 300mg) with digoxin will increased plasma concentration of digoxin. Avoid concomitant of Caprelsa 300mg (Vandetanib 300mg) with agents which may prolong the QT interval.

CONTRAINDICATION of  Caprelsa 300mg (Vandetanib 300mg)

Caprelsa 300mg (Vandetanib 300mg) avoid use in patients with congenital long QT syndrome.

PREGNANCY  of Caprelsa 300mg (Vandetanib 300mg)

Caprelsa 300mg (Vandetanib 300mg) is embryotoxic and fetotoxic, due to pharmacological action treatment will causes risk to fetal when administered to a pregnant woman

LACTATION of Caprelsa 300mg (Vandetanib 300mg)

Advise females not to breastfeed during treatment and for 4 months after final dose.

DOSAGE of  Caprelsa 300mg (Vandetanib 300mg)

The usual dose of Caprelsa 300mg (Vandetanib 300mg) is administrated orally once daily until disease progression or unacceptable toxicity occurs. Avoid crushing of tablets, disperse the tablet in 2 ounces of water by stirring 10 minutes approximately. Be careful, do not use other liquids for dispersion and swallow the medicine soon after dispersion, if any remaining residue with 4 additional ounces of water and swallow.
Th dispersion liquid can be administrated via nasogastric or gastrostomy tubes.

STORAGE  of  Caprelsa 300mg (Vandetanib 300mg)

Caprelsa 300mg (Vandetanib 300mg) tablets should be stored at 25℃.

MISSED DOSE of  Caprelsa 300mg (Vandetanib 300mg)  

If dose is missed, then take the dose as soon as possible before reach of next dose time or skip the missed dose and follow the normal schedule. Do not have extra dose which leads to over dosage. Avoid taking missed dose within 12 hours of the next dose. Consult the doctor about missed dose and overdose.